Abstracts tagged "registry and rheumatoid arthritis (RA)"

Abstract Number: 2041 • 2017 ACR/ARHP Annual Meeting
Practice Improvement Utilizing Six Sigma and Health Informatics in an Academic Setting
Puneet Bajaj¹, Shilu Varghese², Allison Sunleaf², Paul Padilla², Shannon Scielzo², Sherene Philip², Justin Haridas², Clarie Wang², Vaishnavi Kannan², Jeffrey Lewis², Deepa Bhat², Jacqueline Mutz², Duwayne Willett², Jason Fish² and David Karp², ¹Rheumatology, UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX
Background/Purpose: For projects such as the ACR Rheumatology Informatics System for Effectiveness (RISE) to succeed for quality improvement, practice benchmarking, & research, the data included…
Abstract Number: 2453 • 2017 ACR/ARHP Annual Meeting
Methotrexate Discontinuation from Combination Therapy with Adalimumab Is Not Associated with Inferior Outcomes at 6 Months
Dimitrios A. Pappas¹, Chitra Karki¹, Ying Shan¹, Jessica L. Suboticki², Jenny Griffith³ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Methotrexate is frequently administered in combination with biologics for the therapy of Rheumatoid Arthritis (RA) as it leads to superior outcomes compared to biologic…
Abstract Number: 141 • 2017 ACR/ARHP Annual Meeting
Refractory Disease in Rheumatoid Arthritis: Results from the British Society of Rheumatology Biologics Register for Rheumatoid Arthritis
Lianne Kearsley-Fleet¹, Diederik De Cock¹, Kath Watson¹, Maya H. Buch², John D Isaacs³ and Kimme L. Hyrich^1,4, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁴National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Biologic therapy has revolutionised treatment pathways and improved outcomes for patients with Rheumatoid Arthritis (RA) who do not tolerate or respond to conventional synthetic…
Abstract Number: 329 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Worsening Serum Vitamin D Deficiencies in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Masanori Nakayama¹, Takefumi Furuya¹, Eisuke Inoue², Eiichi Tanaka¹, Katsunori Ikari¹, Ayako Nakajima¹, Atsuo Taniguchi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: In 2011, we evaluated serum vitamin D levels in Japanese patients with rheumatoid arthritis (RA) and reported the prevalence of, and factors associated with,…
Abstract Number: 446 • 2017 ACR/ARHP Annual Meeting
Methotrexate Use and Fatigue in Rheumatoid Arthritis Patients: Results from a National Patient Registry
Huifeng Yun¹, Shuo Yang², W. Benjamin Nowell³, Cooper Filby¹, Lang Chen¹ and Jeffrey R. Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX), a synthetic disease-modifying antirheumatic drug (DMARD), is the most commonly used medication for rheumatoid arthritis (RA). Considerable variations between patients taking MTX…
Abstract Number: 600 • 2016 ACR/ARHP Annual Meeting
Disease Activity Trends after Dose Escalation of Infliximab (Remicade) – Results from United States Consortium of Rheumatology Researchers of North America Registry
Dennis Parenti¹, George W. Reed², Ying Shan², Kimberly Dandreo², Joel M. Kremer³ and Raphael J. DeHoratius⁴, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Corrona, LLC, Southborough, MA, ³Albany Medical College, Albany, NY, ⁴Janssen Scientific Affairs, LLC/Sidney Kimmel School of Medicine, Thomas Jefferson University, Horsham/Philadelphia, PA
Background/Purpose: Dose escalation is a common strategy for patients (pts) on infliximab (IFX). This study examined the trend in disease activity across dose escalations to…
Abstract Number: 1221 • 2016 ACR/ARHP Annual Meeting
Environmental Scan of Rheumatoid Arthritis Patient Registries Around the World: An Omeract Initiative
Natalia V. Zamora¹, Maria A. Lopez-Olivo², Robin Christensen³, Niti Goel^4,5, Lars Erik Kristensen⁶, Vibeke Strand⁷, Jeffrey R. Curtis⁸, Beverly Shea⁹ and Maria Suarez-Almazor¹⁰, ¹Section of Rheumatology and Clinical Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁴Rheumatology Center of Excellence, Quintiles, Durham, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁷Biopharmaceutical Consultant, Portola Valley, CA, ⁸Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Clinical Epidemiology & Biostatistics, McMaster University, Health Science Centre Hamilton, Ontario, ON, Canada, ¹⁰Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Patient registries both disease-and drug-based complement information obtained from clinical trials. Long-term outcomes studies can provide information useful for patients. The Agency for Healthcare…
Abstract Number: 1543 • 2016 ACR/ARHP Annual Meeting
Obese Patients with RA Have a More Seropositive and a More Active Disease with Less Deformities
Adeeba Al-Herz¹, Adel Al-Awadhi², Khulood Saleh³, Waleed Al-Kandari³, Eman Hasan⁴, Aqeel Ghanem⁵, Fatemah Abutiban⁶, Ahmad Alenizi⁶, Mohammad Hussain⁴, Yaser Ali⁵, Ibrahim Nahar⁵, Ali Aldei¹, Hebah Alhajeri⁵, Sawsan Hayat⁵, Ahmad Khadrawy³, Ammad Fazal³, Khaled Mokaddem¹, Ajaz Zaman⁵, Ghada Mazloum⁵, Youssef Bartella¹, Sally Hamed¹ and Ahmed Al-Saber⁷, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Faculty of Medicine, Kuwait, Kuwait, ³Rheumatology, Farwania Hospital, Farwania, Kuwait, ⁴Al-Amiri Hospital, Kuwait city, Kuwait, ⁵Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ⁶Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁷Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: An association between obesity and RA activity has been proposed in the literature. Kuwait has the highest obesity rate in The Middle East and…
Abstract Number: 2230 • 2016 ACR/ARHP Annual Meeting
Models Using Claims-Based Administrative Data Are Poor Predictors of Rheumatoid Arthritis Disease Activity in VA Rheumatoid Arthritis (VARA) Patients
Brian Sauer¹, Chia-Chen Teng², Neil Accortt³, Zachary Burningham⁴, David Collier⁵, Mona Trivedi⁶ and Grant W. Cannon⁷, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Center for Observational Research, Amgen, Inc., C, CA, ⁴SLC Veterans Affairs Medical Center, SLC IDEAS Center, Salt Lake City, UT, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Amgen, Thousand Oaks, CA, ⁷Internal Medicine, Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT
Background/Purpose: The goal of this study was to validate a claims-based statistical model to predict disease activity measured by the 28-joint count Disease Activity Score…
Abstract Number: 2239 • 2016 ACR/ARHP Annual Meeting
Patterns of Abatacept Utilization in Patients with Rheumatoid Arthritis. Have the Baseline Characteristics of These Patients Changed over Time?
M. Victoria Hernández¹, Carlos Sánchez-Piedra², Jose Inciarte-Mundo¹, Fernando Sanchez-Alonso², Javier Manero³, Rosa Roselló⁴, Eva Pérez-Pampin⁵, Rosa Morla⁶, Carlos Rodriguez-Lozano⁷, Dolores Ruiz-Montesinos⁸, Raimon Sanmarti¹, Juan J. Gómez-Reino⁵ and BIOBADASER 2.0 Study Group, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology, H San Jorge, Huesca, Spain, ⁵Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, ⁶Arthritis Unit. Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁷Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, ⁸Rheumatology, Hospital Virgen Macarena, Seville, Spain
Background/Purpose: Abatacept (ABA), a T cell co-stimulation inhibitor, was initially approved by the European Medicine Agency (EMA) for patients with rheumatoid arthritis (RA) who had…
Abstract Number: 2496 • 2016 ACR/ARHP Annual Meeting
DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center
Richard Meehan¹, Eric Hoffman², David Muram³, Barbara Goldstein⁴, Jim Crooks⁵ and Pearlanne Zelarney⁶, ¹MEDICINE, National Jewish Health, Denver, CO, ²Medicine/Rheumjatology, National Jewish Health, denver, CO, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology, National Jewish Health, Denver, CO, ⁵Biostatistics, National Jewish Health, Denver, CO, ⁶Bioinformatics, National Jewish Health, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) can be divided into two major subsets based on the presence or absence of antibodies to citrullinated peptide antigens (ACPA). Some…
Abstract Number: 2543 • 2016 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
John Kelsall¹, Anna Jaroszynska², Louis Bessette³, Raman Joshi⁴, Isabelle Fortin⁵, Jacqueline Stewart⁶, Keltie Anderson⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Francois Nantel¹⁰, Karina Maslova¹¹, Brendan Osborne¹², Cathy Tkaczyk¹² and Allen J Lehman¹¹, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Private practice, Burlington, ON, Canada, ³Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁴William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ⁵Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁶Penticton Regional Hospital, Penticton, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is routinely used among rheumatoid arthritis (RA) patients treated with anti-TNF agents to enhance treatment efficacy and minimize the dose of biologic…
Abstract Number: 2597 • 2016 ACR/ARHP Annual Meeting
Time to Initiation of Biologic Agents Is Associated with Glucocorticoid Use: Results from the Corrona Registry
Dimitrios A. Pappas^1,2, Jenny Griffith³, Heather J. Litman², Casey A. Schlacher³, Bob A. Salim⁴, Chitra Karki² and Joel M. Kremer⁵, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³AbbVie Inc., North Chicago, IL, ⁴Axio Research LLC, Seattle, WA, ⁵Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Despite new effective therapies for Rheumatoid Arthritis (RA), glucocorticoids (GC) are widely prescribed. It is possible that dose and duration of GC therapy may…
Abstract Number: 2605 • 2016 ACR/ARHP Annual Meeting
Therapy with Biologic Agents after Diagnosis of Solid Malignancies; Results from the Corrona Registry
Dimitrios A. Pappas^1,2, Sabrina Rebello², Mei Liu², Jennifer Schenfeld³, YouFu Li⁴, David H. Collier³ and Neil Accortt³, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Recently issued guidelines suggest that rheumatoid arthritis (RA) patients with previously treated solid malignancy may be treated as patients without such history (1). The…
Abstract Number: 3211 • 2016 ACR/ARHP Annual Meeting
Early Radiological Progression in Rheumatoid Arthritis Leads to More Long-Term Joint Damage in Daily Clinical Practice; Six Year Radiological Outcomes of a Strict Treat-to-Target Cohort in the Netherlands
Letty G.A. Versteeg¹, Laura M.M. Steunebrink¹, Ina H. Kuper¹, Harald E. Vonkeman², Peter M. ten Klooster³, Arie E. van der Bijl⁴ and Mart A.F.J. van de Laar⁵, ¹Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²koningsplein, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Pcgr, University of Twente, Enschede, Netherlands, ⁴Isala Klinieken, Zwolle, Netherlands, ⁵Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente and University Twente, Enschede, Netherlands
Background/Purpose: Implementation of treat-to-target (T2T) in Rheumatoid Arthritis (RA) leads to limited radiological damage during follow-up of 3 years. Questions are whether these results are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].